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Purpose: Radical cystectomy has been the most widely used method in the treatment 
of bladder cancer, but it is limited by major problems. Therefore, we investigated the 
results of bladder-preserving treatment in patients with T3b, T4a, and T4b transitional 
carcinoma of the bladder who underwent transurethral resection of bladder cancer and 
subsequent administration of chemotherapy.
Materials and Methods: Of all patients who were diagnosed with bladder cancer and 
underwent bladder-preserving treatment between January 2001 and August 2008, 78 
patients with at least 12 months of follow-up data were enrolled in this study. All pa-
tients received gemcitabine (1,000 mg/m
2) and cisplatin (70 mg/m
2) once per month 
postoperatively for a total of 6 months and completed a follow-up visit every 3 months. 
The patient survival rate and prognostic factors (age, tumor size, differentiation, num-
ber of lesions, stage, and presence of hydronephrosis) were assessed. The Kaplan-Meier 
method was used to analyze survival rate, and Cox multiple regression analysis was 
used for prognostic factors.
Results: The mean patient age was 68.32±8.6 years, the mean duration of follow-up 
was 54.70±32.8 months, and the median duration of follow-up was 49.0 months. The 
5-year survival rate was 66.2%. Single lesions were found in 28 cases (35.9%), and multi-
ple lesions were found in 50 cases (64.1%). Stage T3b lesions were identified in 56 cases 
(71.8%), stage T4a lesions were identified in 16 cases (20.5%), and stage T4b lesions 
were identified in 6 cases (7.7%). Tumor size was less than 4 cm in 4 cases (59.0%) and 
greater than 4 cm in 32 (41.0%). Hydronephrosis was present in 21 cases (26.9%). In 
the 5-year survival analysis, prognostic factors significantly influencing survival rate 
were T-stage of the tumor and absence of hydronephrosis and complete regression after 
treatment (p＜0.05). Multivariate analysis revealed that tumor stage and the absence 
of hydronephrosis were statistically significant prognostic indicators. 
Conclusions: In patients with T3b, T4a, and T4b transitional carcinoma of the bladder, 
bladder preservation may prevent a decrease in quality of life. Also, our findings suggest 
that this approach could be considered a primary treatment option for patients with 
T3b stage tumors without evidence of hydronephrosis.
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INTRODUCTION
Current treatment options for muscle-invasive bladder 
cancer include radical cystectomy, chemotherapy, and 
radiotherapy. Recently, in an attempt to preserve the blad-
der - thereby reducing the likelihood of a decreased quality 
of life postoperatively - the combination of transurethral 
resection of the bladder cancer followed by chemotherapy 
and/or radiotherapy has been studied.
　Cystectomy has been the treatment of choice for mus-Korean J Urol 2010;51:525-530
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cle-invasive bladder cancer confined to the organ, and re-
cent improvements in surgical techniques have led to de-
creased rates of complications and mortality following 
surgery. In particular, the development of organ-preserv-
ing surgical procedures has changed the treatment strat-
egies for a variety of tumors; therefore, the previous stand-
ard treatments are being replaced by organ-preserving 
procedures. Over the years, patients have become more 
aware of the complications and decreased quality of life 
that often follow radical cystectomy and are now more in-
sistent upon preserving the bladder. Therefore, chemo-
therapy following transurethral resection of a bladder tu-
mor is gaining more attention in the treatment of bladder 
cancer. 
　Recent studies on bladder-preserving therapy in mus-
cle-invasive bladder cancer by Solsona, Herr, and Shipley 
showed a 5-year survival of 80% and a bladder preservation 
rate of 67-82%, which are highly successful outcomes [1-3]. 
Therefore, it can be expected that appropriately selected 
patients with muscle-invasive bladder cancer treated with 
a combination of transurethral resection of the bladder tu-
mor and chemotherapy could experience outcomes similar 
to those in patients treated with radical cystectomy.
　In this study, we analyzed the prognostic factors affect-
ing the outcomes of T3b, T4a, and T4b transitional carcino-
ma of the bladder treated by transurethral resection of the 
bladder tumor and chemotherapy. Overall, the purpose of 
this study was to evaluate alternative efficacy, prognostic 
factors, and usefulness of bladder preservation treatment 
by analyzing the 5-year survival rate and the treatment’s 
long-term outcomes through follow-up observations on the 
patient group. 
MATERIALS AND METHODS
A total of 78 patients from our institution who were diag-
nosed with T3b, T4a, and T4b transitional carcinoma of the 
bladder and who underwent transurethral resection of the 
bladder tumor and chemotherapy were enrolled in this ret-
rospective study. To be included in the study, a patient had 
to meet the following criteria: 1) be diagnosed with T3b, 
T4a, or T4b transitional carcinoma of the bladder at our in-
stitution from January 2001 to August 2008, 2) have under-
gone transurethral resection of the bladder tumor and be 
followed up for at least 12 months, 3) complete each chemo-
therapy session, 4) patients with one of the above-men-
tioned stages but for whom surgery was not an option be-
cause of accompanying medical illnesses, 5) patients hav-
ing problems of postoperative male sexual dysfunction and 
urinary incontinence or discomfort with urinary diversion, 
6) patients of an old age, and 7) patients who rejected radi-
cal cystectomy as a treatment plan. Except for those cases 
who experienced progression of the tumor during chemo-
therapy, making advancement of the treatment impos-
sible, repeat transurethral resection of the bladder cancer 
was performed in patients with recurrence. 
　Clinical staging of the bladder cancer was done by using 
cystoscopy, computed tomography (CT), bone scan, and 
simple chest X-ray. The stages were assigned by using the 
TNM staging system proposed by the AJCC. Patients with 
urethral or pelvic tumors were excluded. Currently, be-
cause Korea’s medical insurance allows gemcitabine use in 
patients with stage T3b or above, patients at or above that 
stage were selected whether there was lymph node or dis-
tant metastasis. 
　All patients had a serum creatinine concentration of less 
than 2.0 mg/ml, a 24-hour creatinine clearance rate of at 
least 50 mg/min, normal erythropoietic function (WBC≥ 
4,000/mm
3, platelet≥100,000/mm
3), and normal liver 
function (AST/ALT＜40 U/l). The patients’ performance 
status was between 0 and 2 on the basis of the ECOG, and 
each patient's bladder tumor was removed to the maximum 
extent allowed by transurethral resection. Four weeks 
after transurethral resection of the bladder cancer, chemo-
therapy was initiated. The chemotherapy regimen in-
cluded gemcitabine (1,000 mg/m
2) and cisplatin (70 mg/m
2) 
per month for 6 months. Specifically, each session con-
sisted of intravenous gemcitabine and cisplatin at the be-
ginning of the month, followed by a week of rest, two weeks 
of intravenous gemcitabine, and another week of rest. 
　A pelvic CT scan and bone scan were performed every 3 
months to evaluate the patient’s response to the therapy, 
and after completion of the 6-month chemotherapy regi-
men, transurethral cystoscopy, a bladder cytology study, 
and a pelvic CT scan were performed every 2 to 3 months 
for 2 years to monitor for recurrence. Since then, the above 
tests were repeated every 6 month for 3 years; thereafter, 
follow-up was performed every 1 year.
　Age, tumor size, degree of differentiation, number of tu-
mor sites, staging, and the presence of hydronephrosis 
were selected as potential prognostic factors and were in-
cluded in the analysis. The patients were declared cured 
of the tumor when no recurrence occurred. In the case of 
patients who died during follow-up, the relationship be-
tween recurrence and/or progression of the tumor and the 
direct cause of death was studied.
　Both univariate and multivariate analyses were per-
formed to determine whether any of the prognostic factors 
were significantly associated with outcomes after surgery. 
Factors were determined to be statistically significant if 
the p-value was less than 0.05. Survival data were analyzed 
by using the Kaplan-Meier method and log-rank test. To 
run statistical analysis, SPSS for Windows version 17 was 
used. 
RESULTS
Six monthly chemotherapeutic sessions were scheduled 
for a total of 6 months after resection of the tumor. A total 
of 45 patients (58%) received 6 sessions, 23 (29%) received 
2 to 5 sessions, and 10 (13%) received 7 to 12 sessions. The 
mean patient age was 68.32±8.6 years; the mean duration 
of follow-up was 54.70±32.8 months, and the median dura-
tion of follow-up was 49.0 months. A total of 28 patients Korean J Urol 2010;51:525-530
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TABLE 2.  Univariate analysis for disease-specific survival rate of
patients with T3b, T4a, and T4b transitional cell carcinoma of 
the bladder
5-year DSS (%) p-value
Multiplicity
Solitary 71.3  0.794
Multiple 64.2
T stage
T3b 75.8
T4a 46.9  0.018
T4b 40.1
Tumor size
＜4 cm  71.3  0.867
≥4 cm  64.8
Tumor grade
Low 79.6 0.857
High 65.6
Hydronephrosis
Yes 38.9  0.015
No 77.6
Lymph node invasion
Yes 41.8  0.308
No 66.7
DSS: disease-specific survival
TABLE 1. Patient’s characteristics
Characteristics No. of cases (%)
No. of patients  78 (100)
Sex 
Male 69  (88.5)
Female    9 (11.5)
Age (years) 
＜60 15 (15.4)
≥60 63 (84.6)
Tumor size
≥4 cm  46 (59.0)
＜4 cm  32 (41.0)
Differentiation (grade)
Low    5 (6.4)
High 73  (93.6)
Multiplicity
Solitary 28  (35.9)
Multiple 50  (64.1)
Stage
3b 56  (71.8)
4a 16  (20.5)
4b    6 (7.7)
Hydronephrosis
Yes 21  (26.9)
No 57  (73.1)
N stage
N0 63  (80.8)
N1    8 (10.3)
N2    7 (9.0)
M stage
M0 66  (84.6)
M1 12  (15.4)
FIG. 1. Cumulative survival rate.
TABLE 3. Multivariate Cox proportional hazard model for T3b, 
T4a and T4b transitional cell carcinoma of the bladder tumor
Hazard ratio
95% confidence 
interval
p-value
Multiplicity 0.555 0.175-1.761 0.317
T stage
  T3b vs T4a, T4b 3.796 1.157-12.457 0.028
Size 2.610 0.760-8.965 0.127
Tumor grade 0.484 0.760-8.965 0.510
Hydronephrosis 4.743 1.126-19.978 0.034
(35.9%) had a solitary lesion, and 50 (64.1%) had multiple 
lesions. A total of 56 cases (71.8%) were classified as stage 
T3b, 16 (20.5%) were classified as stage T4a, and 6 (7.7%) 
were classified as stage T4b. A total of 46 patients (59.0%) 
had tumors that were less than 4 cm in size, and 32 (41.0%) 
had tumors that were 4 cm in size or greater. On pathology, 
all lesions were classified as urothelial carcinoma; 21 pa-
tients (26.9%) had hydronephrosis, 15 patients (19.2%) had 
lymph node invasion, 12 patients (15.4%) had distant 
metastasis, and 39 patients (50%) had received repeat 
transurethral resection of bladder cancer (Table 1).
　The average 5-year survival rate of the patients was 
66.2% (Fig. 1). Univariate analysis showed that T-stage of 
the tumor, absence of hydronephrosis, and completion of 
the chemotherapy regimen were significantly associated 
with increased survival (Table 2). Multivariate analysis 
using Cox proportional hazards model showed that high tu-
mor stage and presence of hydronephrosis were significant 
prognostic indicators of decreased survival (Table 3, Fig. 
2, 3). 
　Complications were experienced by most patients and 
included alopecia, nausea, vomiting, and loss of appetite. 
Complications such as leukopenia, arising from long-term 
myelosuppression, worsened as time passed; however, ad-
ministration of granulocyte colony-stimulating factor 
(G-CSF) often improved the condition. Korean J Urol 2010;51:525-530
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FIG. 2.  Cumulative survival rate according to tumor stage.
FIG. 3.  Cumulative survival rate according to hydronephrosis.
DISCUSSION
The treatment of muscle-invasive bladder cancer can be 
divided into radical and bladder-preserving therapies, and 
the former is currently considered the standard of care. 
There are alternatives for patients who do not want to un-
dergo radical cystectomy, for reasons such as complica-
tions from the surgery and post-surgical decrease in qual-
ity of life, as well as for patients in whom radical cystectomy 
is contraindicated. However, issues such as delayed initial 
treatment, potential cystectomy in the future, and current 
chemotherapeutic treatment can delay or prohibit per-
formance of the surgery and, therefore, cannot be ignored. 
Furthermore, selecting appropriate patients for blad-
der-preserving procedures can be difficult [4,5].
　Cisplatin-based combination chemotherapy has been re-
ported to be more effective than single-drug regimens; 
therefore, since the 1980s, a combination of transurethral 
resection of the bladder tumor and cisplatin-based combi-
nation chemotherapy or radiotherapy has been used. In our 
study, the mean duration of follow-up was 51.9 months fol-
lowing transurethral resection of the bladder tumor and 
adjuvant chemotherapy, and our patient population 
showed a 5-year survival rate of 66.2%, which is not sig-
nificantly different from the survival rate of similar pa-
tients who undergo radical cystectomy. This means that 
transurethral resection of low-staged muscle-invasive 
bladder cancer without hydronephrosis followed by chemo-
therapy may be equally as efficacious as more radical ther-
apy (e.g., radical cystectomy).
　Accordingly, in the early 1990s, Hashine, Mori, and oth-
ers studied a combination therapy that included in-
tra-arterial cisplatin-based chemotherapy in patients 
with low-stage muscle-invasive bladder cancer, reporting 
an improved 5-year survival rate of 78% to 85% [6,7]. 
　Urinary incontinence is the most problematic complica-
tion affecting the quality of life in patients following radical 
cystectomy. The incidence rate is reported to be 70% to 95% 
during the day and 65% to 85% at night. However, most pa-
tients are willing to accept this complication as an often un-
avoidable result of complete removal of their tumor [4,5,8]. 
Complications of radiotherapy include bladder contraction 
(0-2%) and decreased bladder volume (9%) [9]. In addition, 
Zietman reported that development of erectile dysfunction 
and dissatisfaction with sexual life occurred in 54% and 
59% of patients, respectively, who underwent radical cys-
tectomy [10]. These complications are often significant, 
and it is therefore important to consider these factors when 
choosing the treatment modality for a patient with mus-
cle-invasive bladder cancer.
　During chemotherapy after bladder-preserving sur-
gery, chemotherapy-induced myelosuppression-causing 
leukopenia is the most serious complication, and, for some 
patients, this complication is significant enough to compel 
them to forego completion of their chemotherapy and may 
even lead to death in some cases. However, most of the time, 
administration of G-CSF can reverse these negative effects 
of chemotherapy. Less serious complications, such as alo-
pecia, decreased renal function, oral infection, nausea, 
vomiting, and loss of appetite, disappeared in most pa-
tients when they were off the therapy (i.e., during rest peri-
ods). Disadvantages are under-staging after transurethral 
resection of bladder cancer, no definite patient selection 
criteria, pain incurred during regularly scheduled cysto-
scopy, discomfort and costs of the radiologic tests and che-
motherapy, inconvenience of repeat transurethral re-
section of bladder cancer in recurred cases, and follow-up 
losses during the therapy.
　Complete transurethral tumor resection by a proficient 
urologist, complete remission induced by chemotherapy, 
and exact staging of the cancer through analysis of radio-
logic studies all play important roles in improving the effi-
cacy of bladder-preserving therapy [11]. These factors need 
to be taken into consideration when choosing the appro-
priate treatment modality for a patient with bladder 
cancer. De la Rosa et al found multiple statistically sig-
nificant positive prognostic indicators of survival in pa-
tients with bladder cancer: a tumor size less than 4 cm, a 
tumor with a low degree of differentiation, the presence of 
carcinoma in situ, and good response to chemotherapy [12]. Korean J Urol 2010;51:525-530
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Furthermore, Herr followed up 99 out of 432 patients who 
initially underwent repeated transurethral resection for 
muscle-invasive bladder tumors for 10 years and dis-
covered that 34% of the patients experienced tumor re-
currence [2]. Other potential prognostic factors, both clin-
ical and pathologic, have been studied, and biochemical 
and genetic factors, such as Bcl-2 and P53, are expected to 
provide additional information regarding prognosis. 
　Our study showed that low-stage bladder cancer without 
hydronephrosis can be completely cured by complete tran-
surethral resection of the bladder tumor with adjuvant 
chemotherapy. Even in the case of muscle-invasive cancer, 
a combination of transurethral resection and chemo-
therapy can safely be performed as long as the tumor is of 
a low stage and is limited to the lamina muscularis. 
Bladder-preserving therapy can help to prevent psycho-
logical stress and excessive treatment caused by radical 
cystectomy while improving patients' quality of life and 
promoting normal urination and satisfactory sexual 
activity. Thus, in addition to being an effective treatment 
modality, transurethral resection affords many additional 
benefits to the patient. Also, it must be remembered that 
regular follow-up to monitor for and to treat any recurrence 
is vital to maximizing patient survival. 
　In order to more definitively evaluate the efficacy, bene-
fits, and drawbacks of bladder-preserving surgery, a pro-
spective, randomized study with long-term follow up, com-
paring the outcomes of radical cystectomy versus transure-
thral resection of a bladder tumor, will be required.
CONCLUSIONS
This study followed 78 patients diagnosed with muscle-in-
vasive bladder cancer who underwent transurethral re-
section of the bladder tumor. Their 5-year survival rate was 
66.2%, which is comparable to that of radical cystectomy. 
Prognostic factors associated with decreased survival in-
clude a high-stage tumor and the presence of hydro-
nephrosis. For patients with low-stage tumors and no hy-
dronephrosis, bladder-preserving therapy may be a poten-
tial treatment option that offers not only a survival benefit 
found similarly in more radical therapies, but also an im-
proved quality of life after surgery.
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EDITORIAL COMMENT
This article is a retrospective study of bladder-preserva-
tion therapy for muscle-invasive bladder cancer (MIBC), 
especially T3b and above. Non-muscle-invasive bladder 
cancer (NMIBC), in fact, makes up of 80% of newly diag-
nosed bladder cancer, and approximately 20% is MIBC. 
Furthermore, 20% to 30% of recurred NMIBC becomes in-
vasive and possibly metastatic [1]. For MIBC, radical cys-
tectomy (RC) has been the gold standard of treatment with 
good cancer-specific survival and overall survival [2-4]. 
But, radical surgery on the bladder is accompanied by func-
tional deterioration of continence and sexual behavior [5]. 
This functional deterioration is directly associated with 
the quality of life of bladder cancer patients after RC, and 
for this reason, many MIBC patients are unwilling to un-
dergo RC. For many decades, although many physicians 
have tried to lower the complications and mortality asso-
ciated with RC, the complication rate and perioperative 
rate has been as high as 17% to 32% and 2% to 3%, re-Korean J Urol 2010;51:525-530
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spectively [2]. Of course, in treating bladder cancer, surviv-
al is the first thing to be considered and it is true that surviv-
al is higher than in any other condition. But because the 
quality of life of the patients should not be overlooked, blad-
der-preservation therapy has been studied by many physi-
cians for several decades.
　Including this study, many studies have reported the ef-
ficacy of bladder-preservation therapy [combined chemo-
therapy and radiotherapy (RT) following vigorous tran-
surethral resection of the bladder tumor (TURBT)], which 
has comparable 5-year survival and overall survival [6-9]. 
But no studies have made direct comparisons between the 
two therapies. Because of this, it is difficult to clarify wheth-
er to pay more for good results between RC and blad-
der-preservation therapy. What is more, in the studies of 
the North American Radiation Therapy Oncology Group 
(RTOG) [10] and Massachusetts General Hospital [11], 
large numbers of patients who underwent bladder-preser-
vation therapy eventually required RC (45% and 34%, re-
spectively).
　To successfully conduct bladder-preservation therapy, 
first, observant and careful patient selection should be 
made, and vigorous TURBT should be performed until no 
visible tumor is seen. RT with concomitant radiosensitiz-
ing platinum-based chemotherapy should be accompanied 
in turns, with evaluation of response and prompt salvage 
RC for nonresponders. Last, long-term follow-up of pa-
tients should be done [12]. 
　In conclusion, the study of bladder-preservation therapy 
is ongoing, rather than conclusive. After the accumulation 
of more such studies, a clear choice will be possible for blad-
der-preservation therapy of MIBC. 
Young Deuk Choi
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